Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Humacyte, Inc. (HUMA) Q4 2025 Earnings Call Transcript

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.16 per share a year ago.

- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -

- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. -  - He will work with the Company's leadership team to expand corporate collaborations to accelerate the development and commercialization of Humacyte's broad pipeline - DURHAM, N.C.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter and year ended December 31, 2025 on Friday March 27, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis